The FDA has approved Linzess (linaclotide) for children aged 7 and older with IBS-C, marking the first FDA-approved drug for ...

Rifaximin is as effective as the low-FODMAP diet in managing irritable bowel syndrome and offers quicker symptom relief and ...

The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of irritable bowel syndrome with constipation (IBS-C) in patients 7 years of age and older. Previously, ...

FDA approves IBS drug for children, Linzess, to treat pediatric IBS-C in patients ages 7 and older with proven safety and efficacy.

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...

The FDA approved linaclotide (Linzess) capsules to treat irritable bowel syndrome with constipation (IBS-C) in children age 7 ...

The US medicines regulator has approved Linzess (linaclotide) capsules for children aged seven years and older with irritable ...

The FDA expands use of linaclotide to children as young as age 7 years with irritable bowel syndrome with constipation (IBS-C ...

Therapies to alter behaviour could be the most effective first step to cure irritable bowel syndrome, more than existing go-to treatments, a new study suggests. Irritable bowel syndrome, or IBS, is a ...

Rimegepant is already FDA-approved for acute treatment of migraine and preventive treatment of episodic migraine in adults.

The company now expects revenue of $270 and $275 million for its Ibsrela treatment for the full year, up from $250 million to $260 million previously. The updated outlook comes as Ibsrela continues to ...